Akero Therapeutics, Inc.
AKRO
$48.43
$0.400.83%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 11.52% | 21.61% | 2.96% | 18.67% | 36.30% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 23.02% | 34.91% | 26.11% | 75.27% | 84.52% |
| Operating Income | -23.02% | -34.91% | -26.11% | -75.27% | -84.52% |
| Income Before Tax | -25.93% | -32.58% | -26.89% | -83.33% | -80.12% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -25.93% | -32.58% | -26.89% | -83.33% | -80.12% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -25.93% | -32.58% | -26.89% | -83.33% | -80.12% |
| EBIT | -23.02% | -34.91% | -26.11% | -75.27% | -84.52% |
| EBITDA | -23.01% | -34.90% | -26.08% | -75.29% | -84.57% |
| EPS Basic | -6.57% | 0.02% | -0.17% | -46.82% | -35.07% |
| Normalized Basic EPS | -6.56% | 0.04% | 4.02% | -46.83% | -35.11% |
| EPS Diluted | -6.57% | 0.02% | -0.17% | -46.82% | -34.92% |
| Normalized Diluted EPS | -6.56% | 0.04% | 4.02% | -46.83% | -35.11% |
| Average Basic Shares Outstanding | 18.16% | 32.62% | 26.66% | 24.87% | 33.34% |
| Average Diluted Shares Outstanding | 18.16% | 32.62% | 26.66% | 24.87% | 33.34% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |